By comparing phosphoproteomic analysis of gastric cancer biopsies before and after treatment, the authors were able to gain insight into the impact of the HER2 antibody on the phosphoproteome enabling the discovery of new response biomarkers. The gene discussed is ERBB2; the disease is gastric cancer.